Академический Документы
Профессиональный Документы
Культура Документы
Medication Administration
Vol. 16 Issue 7
July 2015
Page 2
Vol. 16 Issue 7
July 2015
DATE:
UNIT:
Directions: Place the letter of the one best answer in the space provided.
_____1. The majority of adult Americans are overweight or obese.
A. True
B. False
_____2. A person with a body mass index (BMI) of 36 is considered to be:
A. of normal weight
B. overweight
C. obese
D. morbidly obese
_____3. Obesity increases the risk of developing conditions such as:
A. deep vein thrombosis
B. heart failure
C. stroke
D. all of the above
_____4. Physiological changes commonly associated with obesity include:
A. increased lean body mass
B. reduced blood volume
C. higher percentage of total body water
D. decreased cardiac output
_____5. Changes in renal function associated with obesity include increased renal blood flow and a
higher glomerular filtration rate.
A. True
B. False
_____6. Because drug trials typically include obese patients, most drugs currently on the market
have specific data available to guide dosage and frequency for obese patients.
A. True
B. False
_____7. The processes of drug absorption, distribution, metabolism and elimination are known as:
A. pharmacodynamics
B. pharmacokinetics
C. pharmacocompatibility
D. pharmacodiffusion
_____8. Drugs with which of the following characteristics are most likely to require increased
loading doses in the patient with obesity:
A. low volume of distribution
B. water-soluble
C. remains primarily in the blood stream
D. lipid-soluble
_____9. Common renal changes associated with obesity cause:
A. faster clearance of water-soluble drugs from the body
B. faster clearance of lipid-soluble drugs from the body
C. slowed clearance, resulting in drug accumulation in the body
D. no effect on drug levels in the body
_____10. Drug toxicity in obese patients is most likely to occur with drugs that:
A. are eliminated by the kidneys
B. have a narrow therapeutic index
C. are protein-bound
D. are administered orally
Page 2
Unit
Test Date
Score
Additional Information:
Phone: (804) 233-3707
Fax:
(804) 233-3705
Email: editor@peakdev.com
1. Issue:
Month:
2. Facility Information
(provide information about the subscribing facility):
Facility Name: ________________________________
Address: ___________________________________
___________________________________
City: _________________ State: _____ Zip: _______
3. Applicant Information
(provide information about yourself)
Name: ___________________________________
Address: _________________________________
City: ________________ State: _____ Zip: ______
Daytime Phone Number:___________________
Nursing License #: ________________________
Licensing State: __________________________
Previous Peak Development Contact Hours: Yes
No
6. PAYMENT INFORMATION:
APPLICATIONS MUST INCLUDE PAYMENT
Cost: $10 per test nonrefundable
Check Payment method - Provide all information
_______ Check Payable to Peak Development Resources
($40.00 service fee for returned checks)
_______ Credit Card (circle one):
VISA
MASTERCARD
Credit Card Number: ____________________________
Credit Card Expiration Date: ___________
Print Name on Card: ____________________________
Authorized Signature: ___________________________
Billing Address for credit card:
Address: _______________ _____________________
____________________________________
State: ________ Zip: __________
7. EVALUATION
A. How long, in minutes, did it take you to complete
this educational packet? _______minutes.
B.
1.
2.
3.
4.
5.
6.
7.
8.
9.